The US Food and Drug Administration (FDA) on Friday awarded national priority vouchers under the Commissioner’s National Priority Voucher (CNPV) pilot program to two investigational products for their potential to increase access through affordability for American patients.
The products are: enlicitide decanoate - an oral PCSK9 inhibitor for lowering LDL cholesterol under development by Merck & Co (NYSE: MRK); and sacituzumab tirumotecan- a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate, also being developed by Merck.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze